Byondis Seeks Partner For Lead ADC To Enter Crowded Breast Cancer Market
Positive Top-Line Results From TULIP Study
Top-line results from the Phase III TULIP study show that Byondis’s next-generation antibody-drug conjugate, trastuzumab duocarmazine (SYD985) is superior to physicians' choice of therapy for delaying disease progression in patients with advanced HER2-positive breast cancer.
